Literature DB >> 12472293

The Medication Adherence Model: a guide for assessing medication taking.

Mary Jayne Johnson1.   

Abstract

The Medication Adherence Model (MAM) was developed to describe the process of medication adherence and guide health care providers in assessing medication-taking in individuals with hypertension. The MAM was structured with the idea that two types of nonadherence contribute to inconsistent medication taking, the intentional decision to miss medications, and the unintentional interruptions that cause medications not to be taken. The three core concepts identified in the model are: (a) Purposeful Action, (b) Patterned Behavior, and (c) Feedback. Patients' initiating and sustaining medication adherence are dependent on the deliberate decision to take medications based on perceived need, effectiveness, and safety (Purposeful Action). Then they establish medication-taking patterns through access, routines, and remembering (Patterned Behavior). Individuals use information, prompts, or events (Feedback) during the appraisal process to evaluate health treatment that, in return, influences individuals' levels of Purposeful Action and Patterned Behavior (Johnson, 2002; Johnson, Williams, & Marshall, 1999). The MAM depicts the dynamic process of initiating and maintaining medication adherence from the hypertensive patient's perspective. The model describes the key components of existing cognitive and self-regulatory models, and identifies an additional behavioral component. The succinct organization of the MAM may facilitate health care providers' ability to evaluate and individualize interventions for promoting medication taking.

Entities:  

Mesh:

Year:  2002        PMID: 12472293     DOI: 10.1891/rtnp.16.3.179.53008

Source DB:  PubMed          Journal:  Res Theory Nurs Pract        ISSN: 1541-6577            Impact factor:   0.688


  25 in total

1.  Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sofia de Achaval; Maria E Suarez-Almazor
Journal:  Int J Clin Rheumtol       Date:  2010-06-01

2.  Medication adherence behavior and priorities among older adults with CKD: a semistructured interview study.

Authors:  Dena E Rifkin; M Barton Laws; Madhumathi Rao; V S Balakrishnan; Mark J Sarnak; Ira B Wilson
Journal:  Am J Kidney Dis       Date:  2010-07-31       Impact factor: 8.860

3.  Older women's views about prescription osteoporosis medication: a cross-sectional, qualitative study.

Authors:  Kathleen M Mazor; Sarah Velten; Susan E Andrade; Robert A Yood
Journal:  Drugs Aging       Date:  2010-12-01       Impact factor: 3.923

4.  Challenges of adherence and persistence with iron chelation therapy.

Authors:  John B Porter; Michael Evangeli; Amal El-Beshlawy
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

5.  Are we satisfied with the follow-up of hypertensive and chronic kidney disease patients in outpatient clinics?

Authors:  M Peppa; D Vlahakos
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

6.  The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication.

Authors:  Nadir Kheir; William Greer; Adil Yousif; Hajer Al-Geed; Randa Al Okkah; Mahmoud Zirie; Amy Sandridge; Manal Zaidan
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711

7.  Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs.

Authors:  Robert A Yood; Kathleen M Mazor; Susan E Andrade; Srinivas Emani; Wing Chan; Kristijan H Kahler
Journal:  J Gen Intern Med       Date:  2008-09-12       Impact factor: 5.128

8.  Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women.

Authors:  Elaine Lau; Alexandra Papaioannou; Lisa Dolovich; Jonathan Adachi; Anna M Sawka; Sheri Burns; Kalpana Nair; Anjali Pathak
Journal:  Can Fam Physician       Date:  2008-03       Impact factor: 3.275

9.  Assessing the interaction between depressive symptoms and alcohol use prior to antiretroviral therapy on viral suppression among people living with HIV in Rural Uganda.

Authors:  Jacklyn D Foley; Alan Sheinfil; Sarah E Woolf-King; Robin Fatch; Nneka I Emenyonu; Winnie R Muyindike; Allen Kekibiina; Christine Ngabirano; Jeffrey H Samet; Debbie M Cheng; Judith A Hahn
Journal:  AIDS Care       Date:  2020-06-01

10.  Long-term treatment acceptance: what is it, and how can it be assessed?

Authors:  Claire Marant; Juliette Longin; Rémi Gauchoux; Benoit Arnould; Céderic Spizak; Alexia Marrel; Donald L Patrick; Eric Van Ganse
Journal:  Patient       Date:  2012       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.